The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

The field of Cancer Immunity & Immunotherapy is entering an exciting new phase. While Volume I (see here) of this Research Topic highlighted broad ...

A new ‘liquid biopsy’ test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, ...

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- What Is The Projected Market Size Of The Opdivo Nivolumab Market? The Opdivo nivolumab market has seen strong growth in ...

Survival outcomes favored the higher dose: more than 93% of patients in the 70 Gy group were alive one year after treatment, ...